Cargando…

Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia

Detalles Bibliográficos
Autores principales:	Broccoli, Alessandro, Argnani, Lisa, Nanni, Laura, Stefoni, Vittorio, Pellegrini, Cinzia, Casadei, Beatrice, Gugliotta, Gabriele, Carella, Matteo, Coppola, Paolo Elia, Bagnato, Gianmarco, Zinzani, Pier Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10659999/ https://www.ncbi.nlm.nih.gov/pubmed/37738174 http://dx.doi.org/10.1182/bloodadvances.2023010742

Ejemplares similares

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience
por: Stefoni, Vittorio, et al.
Publicado: (2022)

Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients
por: Casadei, Beatrice, et al.
Publicado: (2020)

Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia
por: Broccoli, Alessandro, et al.
Publicado: (2021)

Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience
por: Broccoli, Alessandro, et al.
Publicado: (2021)

Effectiveness of chemotherapy after anti‐PD‐1 blockade failure for relapsed and refractory Hodgkin lymphoma
por: Casadei, Beatrice, et al.
Publicado: (2020)

High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience
por: Derenzini, Enrico, et al.
Publicado: (2015)

The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients
por: Broccoli, Alessandro, et al.
Publicado: (2017)

90‐yttrium‐ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high‐risk follicular lymphoma: updated long‐term results after a median follow‐up of 7 years
por: Casadei, Beatrice, et al.
Publicado: (2016)

BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia
por: Broccoli, Alessandro, et al.
Publicado: (2019)

A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report
por: Broccoli, Alessandro, et al.
Publicado: (2018)

Impressive Continuous Complete Response after Mogamulizumab in a Heavily Pretreated Sézary Syndrome Patient
por: Lolli, Ginevra, et al.
Publicado: (2020)

ABCL-298 Diffuse Large B-Cell Lymphoma During the Covid-19 Pandemic in Two Tertiary Centers: The Israeli/Italian Study
por: Giladi, Odil, et al.
Publicado: (2022)

Poster: ABCL-298 Diffuse Large B-Cell Lymphoma During the Covid-19 Pandemic in Two Tertiary Centers: The Israeli/Italian Study
por: Giladi, Odil, et al.
Publicado: (2022)

Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience
por: Casadei, Beatrice, et al.
Publicado: (2021)

First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi
por: Broccoli, A., et al.
Publicado: (2019)

Management of central nervous system relapse in a young patient affected by primary mediastinal large B‐cell lymphoma: A case report
por: Marangon, Miriam, et al.
Publicado: (2020)

Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS
por: Stefoni, Vittorio, et al.
Publicado: (2020)

A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia
por: Broccoli, Alessandro, et al.
Publicado: (2022)

Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results
por: Stefoni, V, et al.
Publicado: (2016)

Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors
por: Argnani, Lisa, et al.
Publicado: (2022)

P1070: DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE
por: Rusconi, Chiara, et al.
Publicado: (2023)

Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study
por: Casadei, Beatrice, et al.
Publicado: (2022)

Diagnostic accuracy of positron emission tomography/computed tomography-driven biopsy for the diagnosis of lymphoma
por: Broccoli, Alessandro, et al.
Publicado: (2020)

Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy
por: Argnani, Lisa, et al.
Publicado: (2022)

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
por: Pellegrini, Cinzia, et al.
Publicado: (2016)

PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
por: Tarantelli, Chiara, et al.
Publicado: (2021)

Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox
por: Robak, Tadeusz, et al.
Publicado: (2021)

Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study
por: Pagano, Livio, et al.
Publicado: (2022)

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
por: Zinzani, Pier Luigi, et al.
Publicado: (2012)

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma
por: Pellegrini, Cinzia, et al.
Publicado: (2017)

Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma
por: Broccoli, Alessandro, et al.
Publicado: (2017)

Successful treatment of interstitial pneumonia with autoimmune features using rituximab as salvage therapy
por: Kapuczinski, Abeline, et al.
Publicado: (2021)

Docetaxel as Salvage Therapy in Highly Pretreated and Drug Resistant Gastrointestinal Carcinomas
por: Sprinzl, Martin F., et al.
Publicado: (2008)

Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases
por: Visentin, Andrea, et al.
Publicado: (2017)

A BRAF-Negative Classic Hairy Cell Leukemia Patient with Long-Lasting Complete Remission after Rituximab and Pentostatin
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant
por: Chihara, Dai, et al.
Publicado: (2021)

Hairy Mouth
por: Sekar, Shanmuga C, et al.
Publicado: (2012)

Hairy tongue
por: Burge, Eric, et al.
Publicado: (2021)

Hairy Man
Publicado: (1874)

Hairy Esophagus
por: Kurt, İdris
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0b3vcgdanhh8568ejgrtrqd03c